Global News Wire: Novavax Initiating Human Clinical Trials for H7N9 Virus
Novavax, Inc (NVAX) is a clinical-stage biopharmaceutical company that strives to create novel vaccines to treat a broad spectrum of diseases around the world.
Pharma Live: Cytokinetics amending errors in Amyotrophic Lateral Sclerosis Phase IIB Study
Cytokinetics (CYTK) is a clinical stage biotechnology company that focuses on the discovery and development of novel molecular therapeutics in relation to muscle function.
Cognoptix: Simple Eye-Scan Test a Powerful Tool for Diagnosing Alzheimer’s Disease
Cognoptix and its technology have the ability to overhaul commonly accepted Alzheimer’s Disease diagnostic practices, providing a tool to diagnose the disease at an early stage, thereby increasing the efficacy of current therapies.
BioCentury: Orexo is Dissolving Away Opioid Addiction with New Medication
Orexo is an emerging specialty pharmaceutical company in route to enter the market with their new medication Zubsolv; an oral medication that dissolves under the tongue to treat opioid addiction.
“The Value Proposition of the JOBS Act and Reg A” How Will Capital Market Structures Assess Valuation for Smaller Medical Technology Companies After the JOBS Act?
There has been much debate of how the capital market landscape is looking to shape up for bioscience companies with the impending implementation of the […]
Complexa: Novel Treatment for Contrast-Induced Acute Kidney Injury
The Contrast Induced Kidney market is a large one, at about $500 million. This is due to the fact that Acute Kidney Injury affects 3-7% of all patients admitted into hospitals and about 25-30% of patients admitted into the Intensive Care Unit. Complexa’s technology has the potential to treat an issue many sick Americans face today.
Greenestone Healthcare Corp. CEO Discusses Valuation for Canadian Medical Clinics
GreeneStone Healthcare Corp. (OTCBB: GRST) operates medical clinics in Ontario, Canada. GreeneStone adds capacity to an increasingly stretched provincial healthcare system, and provides private alternatives to publicly under-serviced niches. Greenestone President and CEO Shawn Leon spoke with OneMedRadio about market opportunity for clinics in the unique Canadian healthcare system, and evolving valuation drivers in this space.
Metabiomics’ Exec: Test Can Be a Cheaper and More Accurate Alternative to Colonoscopies
Metabiomics is developing a noninvasive screening test for colon polyps in colorectal cancer based on human microbiome markers. In an interview with OneMedRadio, Gregory Kuehn, Vice President of Business Development at Metabiomics, explained that the preliminary data showed “sensitivity in excess of 97%” and specificity “as high as 93%.” Metabiomics will present at the upcoming OneMedForumNY 2013 on June 27th.
Aptiv Solutions Executive Discusses the State of Mobile Health Technology Regulatory
OneMedRadio spoke with Cynthia Nolte, Director, Medical Device Regulatory Services for Aptiv Solutions, about the state of mobile health/health information technology regulatory, clinical trial design for mobile health technology, and what we can expect from future guidelines. The conclusions about regulating a rapidly evolving space — and the case studies that have pioneered this process — are intriguing, and indeed promising.
Functional Neuromodulation CEO: Deep Brain Stimulation a Treatment for Alzheimer’s Disease
Charlottesville, VA-based Functional Neuromodulation is conducting an advanced trial of the application of Deep Brain Stimulation (DBS) therapy as a supplement for current Alzheimer’s Disease treatments. OneMedRadio’s Matt Margolis spoke with Dan O’Connell, co-founder and CEO of Functional Neuromodulation, about the science behind applying Deep Brain Stimulation to Alzheimer’s Disease, its current clinical trial, the lack of venture capital for Alzheimer’s research, and the regulatory obstacles that Functional Neuromodulation will face in the future.